Molecular Partners AG ADR (MOLN) - Total Liabilities
Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has total liabilities worth $21.77 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Molecular Partners AG ADR - Total Liabilities Trend (2013–2025)
This chart illustrates how Molecular Partners AG ADR's total liabilities have evolved over time, based on quarterly financial data. See MOLN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Molecular Partners AG ADR Competitors by Total Liabilities
The table below lists competitors of Molecular Partners AG ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boa Safra Sementes S.A
SA:SOJA3
|
Brazil | R$2.11 Billion |
|
Asia Tech Image
TWO:4974
|
Taiwan | NT$1.50 Billion |
|
Sabina Public Company Limited
BK:SABINA
|
Thailand | ฿557.48 Million |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
Germany | €14.34 Billion |
|
Gobarto S.A.
WAR:GOB
|
Poland | zł942.07 Million |
|
Zig Sheng Industrial Co Ltd
TW:1455
|
Taiwan | NT$3.39 Billion |
|
Bonterra Energy Corp
TO:BNE
|
Canada | CA$474.63 Million |
|
Lin Horn Technology Co Ltd
TWO:5464
|
Taiwan | NT$3.26 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Molecular Partners AG ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MOLN market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecular Partners AG ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecular Partners AG ADR (2013–2025)
The table below shows the annual total liabilities of Molecular Partners AG ADR from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.77 Million | +28.90% |
| 2024-12-31 | $16.89 Million | -22.95% |
| 2023-12-31 | $21.92 Million | -19.08% |
| 2022-12-31 | $27.09 Million | -58.56% |
| 2021-12-31 | $65.38 Million | -18.61% |
| 2020-12-31 | $80.33 Million | +58.13% |
| 2019-12-31 | $50.80 Million | -19.95% |
| 2018-12-31 | $63.45 Million | +129.12% |
| 2017-12-31 | $27.69 Million | -42.67% |
| 2016-12-31 | $48.30 Million | -28.55% |
| 2015-12-31 | $67.60 Million | +48.44% |
| 2014-12-31 | $45.54 Million | -26.31% |
| 2013-12-31 | $61.80 Million | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more